UPDATE: JP Morgan Initiates Cepheid at Overweight on Growth Outlook
JP Morgan initiated coverage on Cepheid (NASDAQ: CPHD) with an Overweight rating and a $47 price target.
JP Morgan noted, "As an early leader in the rapidly-growing molecular diagnostics industry, CPHD already has a large commercial installed base of >2,650 of its GeneXpert systems, which can run any of the company's expanding menu of diagnostic tests; the company has 11 FDA-cleared tests available (14 internationally), a number set to grow to ~25 by 2015, while expanding the addressable market by >$1B. After evaluating competitive offerings, including through a proprietary lab survey, we are confident that the company's market leadership is sustainable."
Cepheid closed at $38.95 on Tuesday.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.